The EPS miss is largely irrelevant for a pre-revenue biotech — the stock will trade on pipeline catalysts. Key near-term events: obexelimab BLA submission (this quarter), EULAR presentation (June 4), and Phase 2 SLE data (Q4 2026). The $718.5M cash runway into 2029 removes near-term financing risk. Watch for any FDA communication on the BLA filing acceptance.
Price Chart
Executive Summary
Zenas BioPharma reported Q1 2026 net loss of $81.0M ($1.46/share), significantly wider than the $33.6M loss a year ago, with zero revenue vs $10M in license revenue in Q1 2025. The EPS miss of -$4.54 vs consensus -$1.54 (-194.8%) reflects the pre-revenue clinical-stage profile, but the company highlighted a strong cash position of $718.5M and key pipeline milestones including obexelimab BLA submission this quarter and Phase 2 SLE data in Q4 2026.
Key Financial Metrics
Key Facts
- Net loss widened to $81.0M from $33.6M YoY, driven by R&D spend up 73% to $60.4M
- Cash, cash equivalents and investments of $718.5M as of March 31, 2026, up from $360.4M at year-end 2025
- Raised $419M YTD from convertible notes, common stock offerings, and ATM sales
- Obexelimab BLA for IgG4-RD on track for submission this quarter; MAA to EMA in H2 2026
- Phase 2 SunStone SLE trial enrollment complete; topline results expected Q4 2026
- First subject dosed in Phase 1 trial of ZB021 (oral IL-17AA/AF inhibitor)
- Cash runway extended into 2029, including potential $75M milestone from Royalty Pharma and $75M from Pharmakon debt facility upon FDA approval
Financial Impact
Net loss of $81.0M in Q1 2026 vs $33.6M in Q1 2025; zero revenue vs $10M license revenue; cash position $718.5M
Risk Factors
- Obexelimab BLA may face regulatory delays or require additional data
- Phase 2 SunStone SLE trial results could miss endpoints
- Dependence on WuXi Biologics for obexelimab manufacturing (China supply chain risk)
- Significant operating losses expected to continue; no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293773 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.65 (+3.52%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.65 (+9.90%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.65 (−16.34%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.65 (−15.05%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.65 (−13.35%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.65 (+48.98%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.65 (+54.99%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.65 (+38.74%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.65 (+38.74%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.65 (+38.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers